Branch² Intelligence

Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key client

IN · 2026-07-10

Key takeaway

OneSource Specialty Pharma shares fell 7.4% after a key client cut guidance and delayed semaglutide supply.

Step 1Key client delays semaglutide supply and cuts guidance, reducing OneSource's order book.
Step 2OneSource's revenue visibility drops, leading to lower capacity utilization and margin pressure.
Step 3Investor re-rating of OneSource's growth profile as GLP-1 exposure becomes less certain.

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.